| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 05, 2026 | Sale | $9.21 | 11,903 | 109,627 | 121,249 | Jan 07, 2026, 04:04 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 03, 2025 | Sale | $12.18 | 9,557 | 116,404 | 87,666 | Jan 07, 2025, 05:20 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 03, 2024 | Sale | $29.46 | 5,843 | 172,135 | 54,372 | Jan 05, 2024, 04:50 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 01, 2024 | Option/RSU Exercise | - | 3,187 | - | 60,215 | Jan 03, 2024, 05:34 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 04, 2023 | Sale | $37.21 | 2,574 | 95,779 | 25,687 | Jan 06, 2023, 05:26 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 01, 2023 | Option/RSU Exercise | - | 3,187 | - | 28,261 | Jan 04, 2023, 08:33 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 01, 2022 | Option/RSU Exercise | - | 3,187 | - | 11,973 | Mar 03, 2022, 08:00 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Jan 01, 2022 | Sale | $112.24 | 1,051 | 117,964 | 10,922 | Mar 03, 2022, 08:00 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Nov 05, 2021 | Option/RSU Exercise | $12.62 | 2,400 | 30,288 | 11,114 | Nov 09, 2021, 06:08 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Nov 05, 2021 | Sale | $132.72 | 2,400 | 318,535 | 9,914 | Nov 09, 2021, 06:08 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Oct 14, 2021 | Sale | $128.44 | 2,400 | 308,249 | 10,563 | Oct 15, 2021, 07:02 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Oct 14, 2021 | Option/RSU Exercise | $12.62 | 2,400 | 30,288 | 11,114 | Oct 15, 2021, 07:02 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Sep 24, 2021 | Option/RSU Exercise | $12.62 | 7,923 | 99,988 | 8,714 | Sep 27, 2021, 04:15 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Sep 21, 2021 | Option/RSU Exercise | $12.62 | 2,400 | 30,288 | 3,191 | Sep 23, 2021, 05:48 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Sep 21, 2021 | Sale | $149.81 | 2,400 | 359,544 | 791 | Sep 23, 2021, 05:48 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Aug 30, 2021 | Sale | $158.04 | 2,400 | 379,300 | 2,991 | Sep 01, 2021, 07:32 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Aug 30, 2021 | Option/RSU Exercise | $12.62 | 2,400 | 30,288 | 3,191 | Sep 01, 2021, 07:32 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Aug 09, 2021 | Option/RSU Exercise | $12.62 | 2,400 | 30,288 | 3,191 | Aug 11, 2021, 04:50 PM |
| NTLA | | Intellia Therapeutics, Inc. | David Lebwohl | EVP, Chief Medical Officer | Aug 09, 2021 | Sale | $164.05 | 2,400 | 393,720 | 791 | Aug 11, 2021, 04:50 PM |
